Please wait while the formulary information is being retrieved.
ONPATTRO (patisiran sodium, lipid complex)
- Transthyretin familial amyloid polyneuropathy
2 mg/mL intravenous solution
- Infuse 0.3 mg/kg over approximately 80 minute(s) by intravenous routeevery 3 weeks not to exceed 30 mg
Transthyretin familial amyloid polyneuropathy
- Infuse 0.3 mg/kg over approximately 80 minute(s) by intravenous routeevery 3 weeks not to exceed 30 mg
- Infuse 30 mg over approximately 80 minute(s) by intravenous route every 3 weeks (for patients weighing greater than or equal to 100 kg)
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
ONPATTRO (patisiran sodium, lipid complex)
- Transthyretin familial amyloid polyneuropathy
- Vitamin A deficiency
- Acute abdominal pain
- Back pain
- Dyspnea
- Flushing
- Nausea
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Atrioventricular block
- Arthralgias
- Blurred vision
- Bronchitis
- Dry eye
- Dyspepsia
- Headache disorder
- Muscle spasm
- Vertigo
- Vitreous floater
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Extravasation injury
- Hypotension
- Syncope
Less Severe
- Skin inflammation
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Patisiran
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Patisiran
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Patisiran
Insuff data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Transthyretin familial amyloid polyneuropathy | |
| E85.1 | Neuropathic heredofamilial amyloidosis |
| E85.82 | Wild-type transthyretin-related (ATTr) amyloidosis |
| G63 | Polyneuropathy in diseases classified elsewhere |
| 0-9 | A-Z |
|---|---|
| E85.1 | Neuropathic heredofamilial amyloidosis |
| E85.82 | Wild-type transthyretin-related (ATTr) amyloidosis |
| G63 | Polyneuropathy in diseases classified elsewhere |
Formulary Reference Tool